Literature DB >> 22461529

Added value of use of a purified protein derivative-based enzyme-linked immunosorbent spot assay for patients with Mycobacterium bovis BCG infection after intravesical BCG instillations.

Karen A Heemstra1, Ailko W J Bossink, Roan Spermon, John J M Bouwman, Robert van der Kieft, Steven F T Thijsen.   

Abstract

In this case series, we describe four cases in which the use of gamma interferon release assays with purified protein derivative (PPD) as a stimulating antigen was able to demonstrate PPD-specific immune activation. This may help to improve the adequate diagnosis of (systemic) Mycobacterium bovis BCG infections after intravesical BCG instillations for bladder carcinoma.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22461529      PMCID： PMC3370454          DOI： 10.1128/CVI.05597-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  25 in total

1.  Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection.

Authors:  J A Streeton; N Desem; S L Jones
Journal:  Int J Tuberc Lung Dis       Date:  1998-06       Impact factor: 2.373

2.  Cell-mediated immune response to tuberculosis antigens: comparison of skin testing and measurement of in vitro gamma interferon production in whole-blood culture.

Authors:  R K Katial; J Hershey; T Purohit-Seth; J T Belisle; P J Brennan; J S Spencer; R J Engler
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis.

Authors:  P D Johnson; R L Stuart; M L Grayson; D Olden; A Clancy; P Ravn; P Andersen; W J Britton; J S Rothel
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 4.  The tuberculin skin test.

Authors:  R E Huebner; M F Schein; J B Bass
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

5.  Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis.

Authors:  C S Hirsch; Z Toossi; J L Johnson; H Luzze; L Ntambi; P Peters; M McHugh; A Okwera; M Joloba; P Mugyenyi; R D Mugerwa; P Terebuh; J J Ellner
Journal:  J Infect Dis       Date:  2001-02-08       Impact factor: 5.226

6.  Reliability of tuberculin skin test measurement.

Authors:  J Pouchot; A Grasland; C Collet; J Coste; J M Esdaile; P Vinceneux
Journal:  Ann Intern Med       Date:  1997-02-01       Impact factor: 25.391

7.  Cytokine production at the site of disease in human tuberculosis.

Authors:  P F Barnes; S Lu; J S Abrams; E Wang; M Yamamura; R L Modlin
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

9.  Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG.

Authors:  M Harboe; T Oettinger; H G Wiker; I Rosenkrands; P Andersen
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria.

Authors:  R E Weir; P E M Fine; B Nazareth; S Floyd; G F Black; E King; C Stanley; L Bliss; K Branson; H M Dockrell
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330
View more
  1 in total

Review 1.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.